HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Ramelteon combined with an α1-blocker decreases nocturia in men with benign prostatic hyperplasia.

AbstractBACKGROUND:
Nocturia is defined as waking one or more times during the night due to the urge to void. Recently, the effectiveness of several sedatives and analgesics for nocturia has been reported. We herein investigated the effects of ramelteon, an antioxidant and sleep inducer, on nocturia unresponsive to α1-blocker monotherapy in males with lower urinary tract symptoms (LUTS) as a pilot study.
METHODS:
Subjects were 19 patients who had LUTS suggestive of benign prostate hyperplasia, received α1-blockers (tamsulosin, silodosin, or naftopidil), and continued to have two or more episodes of nocturia per night before starting ramelteon. Ramelteon at 8 mg once daily for one month was added to the α1-blocker. A self-administered questionnaire including the International Prostate Symptom Score (IPSS), quality of life (QoL) index, Overactive Bladder Symptom Score (OABSS), and Nocturia Quality-of-Life Questionnaire (N-QOL) were assessed before and one month after starting ramelteon.
RESULTS:
The mean score on IPSS question 7 (nocturia) decreased significantly from 2.88 before starting ramelteon to 2.41 one month after starting the medication (P = 0.03). The mean total OABSS decreased significantly from 6.31 to 5.38 (P = 0.03), and the mean for OABSS question 2 (nighttime frequency of nocturia) also significantly decreased from 2.63 to 2.13 (P = 0.01). The mean total N-QOL score did not change significantly. Two patients had dizziness; the remaining patients had no adverse drug-related events.
CONCLUSIONS:
Ramelteon in combination with an α1-blocker could be a treatment option for reducing nocturia in men with BPH.
AuthorsTakashi Kawahara, Satoshi Morita, Hiroki Ito, Hideyuki Terao, Ryoko Sakata, Hitoshi Ishiguro, Katsuyuki Tanaka, Hiroshi Miyamoto, Junichi Matsuzaki, Yoshinobu Kubota, Hiroji Uemura
JournalBMC urology (BMC Urol) Vol. 13 Pg. 30 ( 2013) ISSN: 1471-2490 [Electronic] England
PMID23758651 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adrenergic alpha-1 Receptor Antagonists
  • Antioxidants
  • Indenes
  • ramelteon
Topics
  • Adrenergic alpha-1 Receptor Antagonists (administration & dosage)
  • Aged
  • Antioxidants (administration & dosage)
  • Drug Therapy, Combination
  • Humans
  • Indenes (administration & dosage)
  • Male
  • Nocturia (diagnosis, etiology, prevention & control)
  • Pilot Projects
  • Prostatic Hyperplasia (complications, diagnosis, drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: